NextCure, Inc. filings document a clinical-stage oncology issuer's financial reporting, governance, capital structure, and material-event disclosures. Recent Form 8-K reports furnish quarterly and annual results, business update exhibits, Regulation FD materials on ADC programs, officer transition disclosure, a completed private placement of common stock and pre-funded warrants, and an effected reverse stock split.
The company's proxy materials cover annual meeting matters including director elections, auditor ratification, say-on-pay, board governance, and executive compensation for a Delaware corporation with Nasdaq-listed common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
FAQ
How many NextCure (NXTC) SEC filings are available on StockTitan?
StockTitan tracks 71 SEC filings for NextCure (NXTC), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.
When was the most recent SEC filing for NextCure (NXTC)?
The most recent SEC filing for NextCure (NXTC) was filed on June 23, 2025.